Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Methylation Signature Identified for Brain Metastases of Lung Cancer

By LabMedica International staff writers
Posted on 17 Oct 2019
When lung cancer metastasizes to the brain, it means the primary lung cancer has created a secondary cancer in the brain. More...
About 20% to 40% of adults with non-small cell lung cancer go on to develop brain metastases at some point during their illness.

DNA methylation is a process by which methyl groups are added to the DNA molecule. Methylation can change the activity of a DNA segment without changing the sequence. When located in a gene promoter, DNA methylation typically acts to repress gene transcription.

Scientists at the Zhejiang Cancer Hospital (Hangzhou, China) performed capture-based targeted sequencing to look for somatic mutations in 60 treatment-naïve advanced non-small cell lung cancer (NSCLC) patients using a panel of 520 cancer-related genes, as well as DNA methylation analyses using a methylation panel consisting of 100,000 CpG sites. The patients were split into three groups: one with brain metastases, a second with leptomeningeal metastases, and the third with no metastases.

The team identified 370 mutations in the lung primary lesions and 574 mutations in the brain metastases. Among them, 242 mutations were shared, of these, 128 were lung primary-specific and 332 were brain-specific. Among the mutations specific to the brain metastases, 82% of them were copy number variations (CNVs), which was significantly higher than the CNVs found in the primary tumors. Only 16% of the CNVs were found in both the lungs and the brain. The investigators also performed a pathway analysis of the genes that were only mutated in the brain and found an enrichment of genes in the PI3K-AKT and focal adhesion pathways.

In the leptomeningeal metastasis group, the team found a significant concordance between the driver mutations in primary lung tissue and the metastases in cerebrospinal fluid. These metastases, however, did not have a significantly larger number of CNVs than the primary tumors. They also found that the list of mutated genes was comparable in all three patient cohorts; they next turned to DNA methylation analysis to see if they could find any markers indicating a higher likelihood of developing metastasis.

The methylation analysis revealed distinct patterns, with 268 methylation blocks being significantly differentially methylated between primary lung lesions and brain metastases. Among those, 211 blocks were hypermethylated in the brain and the remaining 57 blocks were hypermethylated in lung lesions. When they compared the leptomeningeal metastases to the non-metastatic patients, they found 323 blocks that were differentially methylated. Of these, the brain and leptomeningeal metastasis groups shared 15 methylation blocks that the scientists believe may be prognostic of central nervous system metastasis. Through a stepwise regression analysis, the team was able to narrow the signature further to six methylation blocks. The study was presented at the Annual meeting of the European Society for Medical Oncology held September 27- October 1, 2019, in Barcelona, Spain.

Related Links:
Zhejiang Cancer Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.